Skip to content
Screener

Upstream Bio, Inc. UPB Q2 2026 earnings

Reported August 11, 2026 · Before market open

Revenue$773.0KBeat by $211.6K
EPS-$0.73Beat by $0.05
Revenue estimate$561.4K
EPS estimate-$0.78
“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027. Our End-of-Phase 2 interactions with the FDA are on schedule, and we look forward to sharing more details about our Phase 3 development plans soon. With more than 500 participants treated in verekitug clinical trials thus far, and with compelling Phase 2 results now demonstrated in both severe asthma and CRSwNP, we have built a substantial and consistent body of clinical evidence supporting verekitug's potential to deliver durable, best-in-class efficacy with convenient quarterly dosing. In addition, our CMC and device development efforts continue to advance, and we are working diligently to provide options for both at-home and in-office administration at launch.”
Rand Sutherland

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$522.5K
EPS estimate-$0.73

Financials

Q2 2026

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$390.52M-56.6%
Enterprise value$312.07M-63.6%
P/S123.7×-207×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%—
Debt / equity0×0.0×
Current ratio28×-10.3×

FAQ

When did Upstream Bio, Inc. report Q2 2026 earnings?
Upstream Bio, Inc. (UPB) reported Q2 2026 earnings on August 11, 2026 before market open.
What were Upstream Bio, Inc.'s Q2 2026 revenue and EPS?
Upstream Bio, Inc. reported revenue of $773.0K and eps of $-0.73 for Q2 2026.
Did Upstream Bio, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $561.4K by $211.6K. EPS beat the consensus estimate of $-0.78 by $0.05.
How did Upstream Bio, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 17.5% from $937.0K a year earlier and eps grew 1.4% from $-0.74.
Where can I find Upstream Bio, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-343407) and the 10-Q periodic report (0001193125-26-343417) directly on SEC EDGAR. The filing index links above go to sec.gov.